Bordeaux

• Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended recruitment
  2024-514480-26-00 4 2022-10-12 Post-menopausal women with localized luminal A breast cancer and consi
• A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) Ended recruitment
  2024-514930-19-00 9 2022-10-07 metastatic and/or unresectable gastrointestinal stromal tumors (GIST)
• Evaluation of the Efficacy of 3-month Continuous Extended Treatment With Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults: … Ended recruitment
  2024-517239-33-00 5 2022-10-06 Ear, nose and throat diseases
• Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human … Ended recruitment
  2024-517024-20-00 9 2022-09-27 Metastatic colorectal cancer patients
• A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t … Ended recruitment
  2024-511917-40-00 4 2022-09-13 Advanced Upper Gastrointestinal Tract Malignancies
• Binimetinib, Encorafenib and Pembrolizumab COmbination in MElanoma - Metastatic to the Brain Ended recruitment
  2023-505302-42-00 4 2022-09-05 BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
• A research study to compare somapacitan once a week with Norditropin® once a day in children who need help to grow Ended recruitment
  2023-506927-27-00 5 2022-08-29 Children with short stature either born small for gestational age or w
• Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended recruitment
  2023-507933-12-00 5 2022-08-18 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended recruitment
  2024-511068-10-00 5 2022-08-04 Sjögren’s Syndrome
• A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Ended recruitment
  2024-513611-28-00 4 2022-07-29 Metastatic Solid Tumors
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance … Ended recruitment
  2023-504996-26-00 5 2022-07-21 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n … Ended recruitment
  2023-508559-37-00 5 2022-07-14 Lupus nephritis
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• Avalglucosidase alfa French post-trial access for participants with Pompe disease Ended recruitment
  2024-514773-22-00 6 2022-07-11 Glycogen storage disease type II
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended recruitment
  2023-510054-16-00 4 2022-04-26 Primary Sjogren's syndrome
• Open-Label and Long-term Extension Study with Dersimelagon (MT-7117) in Subjects with EPP or XLP Ended recruitment
  2024-514466-38-00 5 2022-04-19 Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
• A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarco … Ended recruitment
  2024-517528-20-00 4 2022-04-19 Unresectable or metastatic conventional chondrosarcoma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended recruitment
  2023-506359-68-00 5 2022-04-08 Active Proliferative Lupus Nephritis
• Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended recruitment
  2023-504597-37-00 5 2022-03-25 Focal segmental glomerulosclerosis
• TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SA … Ended recruitment
  2023-509498-21-00 4 2022-03-16 Adult patients with treatment-naïve surgically non-metastatic and rese

Showing 697–720 of 1,096 trials